Igc pharma's phase 2 clinical trial interim data demonstrates significant reduction in sleep disturbances

- igc-ad1 could offer safer alternative to existing sleep medications for alzheimer's - potomac, md / access newswire / march 26, 2025 / igc pharma, inc. (nyse american:igc) ("igc pharma" or the "company") today announced additional positive interim results from its ongoing phase 2 clinical trial on igc-ad1, an investigational treatment for agitation in dementia due to alzheimer's disease. based on the interim analysis at week 2 sleep disturbance was reduced by about 71% (p=.012) and at week 6 about 78% (p=.02) for those on the active medication.
IGC Ratings Summary
IGC Quant Ranking